Pegylated Lipoprotein Nanoparticles Treat Neurodegenerative Diseases
Summary
The USPTO published patent application US20260097095A1 for pegylated reconstituted high-density lipoprotein nanoparticles designed to prevent or treat neurodegenerative diseases. The application, filed by inventors Lee, Kim, and Kim on October 10, 2025, was published on April 9, 2026.
What changed
The USPTO published patent application US20260097095A1 covering pegylated reconstituted high-density lipoprotein nanoparticles and methods for preventing or treating neurodegenerative diseases. The nanoparticles feature a phospholipid layer protected by PEGylation, which allows them to evade immune system rejection while maintaining the ability to cross the blood-brain barrier.
Pharmaceutical companies developing nanoparticle-based drug delivery systems should monitor this application, as it may affect freedom-to-operate considerations for similar nanomedicine platforms targeting neurodegenerative conditions. Biotech firms and medical device manufacturers working with lipid-based carriers should also review the claims for potential overlap with their own R&D programs.
What to do next
- Monitor for updates
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES
Application US20260097095A1 Kind: A1 Apr 09, 2026
Inventors
Wooseung LEE, Jin KIM, Yong Tae KIM
Abstract
PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases are provided. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.
CPC Classifications
A61K 38/17 A61K 9/5169 A61K 47/10 A61P 25/28 B82Y 5/00
Filing Date
2025-10-10
Application No.
19355472
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.